ADVENT On Air

ADVENT On Air

By ADVENT ProgramMedicineHealth & Fitness
Download on the App Store

ADVENT On Air episodes

  • Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

    Join Profs. Brusselle and Backer as they discuss the concept of disease modification in asthma. Join them as they highlight  the concept of disease modification in severe asthma, how it can be defined and objectively assessed, and the benefits for the patient when disease modification is a treatment target.

     

    ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  


    This podcast is intended for healthcare professionals only.


    Disclaimer:

    • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
    • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
    • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits

      • Speaker disclosures:  

      • Dr. Vibeke Backer: has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC.
      • Dr. Guy Bruselle:  has received grants from Merck Sharp & Dohme and has recevied lecturer/consultant fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Sanofi

        •  

        © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

        MAT-GLB-2503097 - 1.0 - 01/2026

        MAT-US-2600873 v1.0 - P Expiration Date: 01/28/2028

        21 min
      • Be on the Lookout for EoE: The Importance of Early Diagnosis

        Hear Dr. Seema Aceves and Ms. Hilary Ugras discuss the importance of early diagnosis and intervention for patients with EoE, opportunities for early diagnosis, and unmasking the adaptive behaviors of patients with EoE. 

        ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. 

        Learn more at ADVENTprogram.com. 

        This podcast is intended for healthcare professionals only. 

        Disclaimer:  

        • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. 

          • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program 

            • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits 

               

              Speaker disclosures:  

              • Dr. Seema Aceves: Research funding: NIH, NIAID, NIDDK . Honoraria and/or consultation fees: AstraZeneca, Medscape, UpToDate, Regeneron, Sanofi, Ferring . Other support: Royalties, Co-inventor, oral viscous budesonide (UCSD-patented, Takeda-licensed) 
                • Ms. Hilary Ugras: Consultant/Speaker/Advisory Board: Regeneron, Sanofi, Takeda 

                  • © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. 

                  MAT-GLB-2506205 - 1.0  - 01/2026 

                  MAT-US-2512929 v1.0 - P Exp Date: 01/23/2028 

                  19 min
                • Predictors of Recurrence in CRSwNP

                  Hear Drs. Katie Buchheit and Martin Wagenmann discuss the rates of recurrence following endoscopic sinus surgery for patients with CRSwNP and different methods of predicting which patients will respond well to surgery and which patients would fare better with a different approach.


                  ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.


                  This podcast is intended for healthcare professionals only.

                  Disclaimer:

                  • This program is non-promotional and is sponsored by Sanofi and
                    • Regeneron Pharmaceuticals, Inc.
                  • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
                  • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits

                    • Speaker disclosures:  

                    • Dr. Katie Buchheit: K. Buchheit has served on scientific advisory boards and/or received honoraria from AstraZeneca, Regeneron, Sanofi-Genzyme, Eli Lilly and GlaxoSmithKline, receives royalties from UpToDate, and receives research funding from NIH/NIAID and Regeneron.
                    • Dr. Martin Wagenmann: Fees for lectures and / or participation in scientific advisory boards: Advanz Pharma, ALK-Abelló, Allergopharma, AstraZeneca, Celltrion, CSL Behring, GSK, HAL Allergie, med update, MSD, NeilMed, Regeneron, Sanofi, Stallergenes, Streamed Up; Grants (to institution): ALK-Abelló, AstraZeneca, EU, GSK, Novartis, Regeneron, Sanofi, Takeda

                      • © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.


                      MAT-GLB-2506006 - 1.0  - 1/2026

                      MAT-US-2600233 v1.0 - P Exp Date: 01/07/2028

                      22 min
                    • Best Practice for CSU - Perspectives from Allergy and Dermatology

                      Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria. offering practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients.


                      ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.


                      This podcast is intended for healthcare professionals only.


                      Disclaimer:

                      • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
                      • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
                      • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.

                        • Speaker disclosures:

                        • Nicole Chase, MD, has the following interests to disclose: ALK, Amgen, Apogee, ARS, AstraZeneca, Aquestive, Blueprint, Cogent, Eli Lilly, Genentech, Illuminate Health, Incyte, MJH Life Sciences, Novartis, Onviv, Regeneron, Sanofi, Regeneron, Vindico.
                        • Jason Hawkes, MD, MS has the following interests to disclose: Medical Board, National Psoriasis Foundation Scientific Advisory Committee, Apogee, Arcutis Biotherapeutics, Boehringer Ingelheim, Blueprint Medicines, Bristol Myers Squibb, Boxer Capital LLC, Cogent Biosciences, Galderma, Institute for Systems Biology, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi, SUN Pharma, Takeda, UCB.


                          • © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

                          MAT-GLB- MAT-GLB-2506315 – 1.0 – 01/2026

                          MAT-US-2514202 v1.0 - P Expiration Date: 12/24/2027

                          29 min
                        • Eosinophilic Esophagitis: Steering Toward Success

                          Hear Drs Evan Dellon and Joshua Wechsler discuss EoE assessment utilizing the latest guidance from both US and European guidelines. Join them as they discuss current approaches to assess treatment response, the need for maintenance therapy, and the importance of follow-up and looking beyond symptom improvement to define therapeutic success.  



                          ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  


                          This podcast is intended for healthcare professionals only.

                          Disclaimer:

                          • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
                          • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
                          • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits

                            • Speaker disclosures:  

                            • Dr. Evan Dellon: Research funding:  Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Dr. Falk Pharma, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Sanofi, Shire/Takeda, Uniquity; Consultant:  Abbvie, Adare/Ellodi, Alfasigma, ALK, Allakos, Amgen, Apogee, Apollo, Aqilion, Arena/Pfizer, AstraZeneca, Biocryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, Domain, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, Upstream Bio; Educational grant:  Allakos, Aqilion, Holoclara, Invea 
                            • Dr. Joshua Wechsler: Medical advisory/speaker/consultant: Regeneron/Sanofi; Consultant: AstraZeneca, Ellodi, Celldex; Medical Advisory: BMS 

                              • © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.


                              MAT-GLB-2503560 - 2.0 - 12/2025

                              17 min
                            • Exploring the Urgency to Treat Patients with Atopic Dermatitis

                              Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.

                               

                              ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

                               

                              This podcast is intended for healthcare professionals only.

                               

                              Disclaimer:

                              • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
                              • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
                              • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.

                                •  

                                Speaker disclosures:

                                • Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi. 

                                 

                                © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

                                MAT-GLB-2407353  – 1.0 – 02/2025

                                MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027

                                15 min
                              • Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

                                Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma.


                                ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.

                                 

                                This podcast is intended for healthcare professionals only.

                                 

                                Disclaimer:

                                • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
                                • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program.
                                • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.


                                  • Speaker disclosures:

                                  • Mario Castro, MD, MPH, reports grants and research support from NIH, ALA, PCORI, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi, and Theravance. He receives consulting fees from Genentech, Teva, Sanofi-Aventis, Merck, Novartis, Arrowhead Pharmaceuticals, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines, and GSK. He receives payment for speaker bureau activities from Amgen, AstraZeneca, Genentech, Regeneron, Sanofi-Aventis, and Teva. He also receives stock options from Aer Therapeutics.
                                  • Vibeke Backer, MD, has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC.


                                    • © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

                                    MAT-GLB-2401489 – 1.0 – 10/2024

                                    MAT-US-2410093 v1.0 – P Expiration Date: 10/09/2026

                                    20 min
                                  • Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

                                    Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.


                                    ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.


                                    This podcast is intended for healthcare professionals only.


                                    Disclaimer: 

                                    • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
                                    • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
                                    • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


                                      • Speaker disclosures:

                                      • Theresa Guilbert, MD, reports grants from GSK, grants from NIH, grants and consult fees from Sanofi/Regeneron/Amgen, grants and consult fees from AstraZeneca, consult fees from Genentech, consult fees from Polarean, grants and consult fees from OM Pharma, consult fees from AiCME, consult fees from Best Pharmaceuticals for Children Act (BPCA), consult fees from PlatformQ health, royalties from UpToDate. 
                                      • Wanda Phipatanakul MD, MS, consults for Genentech, Novartis, Sanofi, Regeneron, GSK, AstraZeneca.


                                        • © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

                                        MAT-GLB-2401186 - 1.0  - 08/2024

                                        MAT-US-2408147 v1.0 - P Exp Date: 08/14/2026

                                        23 min
                                      • Exploring PN as a Distinct and Unique Disease

                                        Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique characteristics of prurigo nodularis (PN) and its clinical definition and explore how some of these characteristics are shared with atopic dermatitis, including underlying type 2 inflammation. They also discuss the need to raise awareness of this disease among both physicians and patients and educate that this is not a psychodermatological disorder.


                                        ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.


                                        This podcast is intended for healthcare professionals only.


                                        Disclaimer: 

                                        • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
                                        • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
                                        • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


                                          • Speaker disclosures:

                                          • Dr. Shawn Kwatra is an advisory board member/consultant for Abbvie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi.
                                          • Dr. Sonja Ständer was speaker and/or consultant and/or Investigator and/or has received research funding from AbbVie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, German Research Foundation (DFG), Integrity CE, Kiniksa, Leo Pharma, L’Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor, and WebMD.


                                            • © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

                                            MAT-GLB-2400085- 1.0 - 08/2024

                                            MAT-US-2408113 v1.0-P Expiration Date: 08/13/2026

                                            31 min
                                          • Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

                                            Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.


                                            ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.


                                            This podcast is intended for healthcare professionals only.


                                            Disclaimer: 

                                            • This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
                                            • The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
                                            • The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits


                                              • Speaker disclosures:

                                              • April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx
                                              • Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi. 


                                                • © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

                                                MAT-GLB-2401395 - 2.0 - 08/2026

                                                MAT-US-2407636 v2.0 - P 08/2026 

                                                Updated Expiration Date: 08/04/2028

                                                24 min

                                              About ADVENT On Air

                                              From the publisher's feed

                                              The latest updates in type 2 inflammatory science, brought to you by leading experts in the field.